Keep Social: A 7-Week Program for Young Adults with Cancer
Official title: Keep Social Randomized Controlled Trial for Young Adults With Cancer
Run by UNC Lineberger Comprehensive Cancer Center · NCT07788339 · Data updated 2026-11-12
This trial tests whether a social connectedness intervention delivered via a simulated social media platform can improve social and emotional well-being for young adults in the US who were diagnosed with cancer as adolescents or young adults.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 22 Years to 39 Years |
| Sex | All |
| Enrollment | 395 (estimated) |
| Sponsor | UNC Lineberger Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Chapel Hill, North Carolina) |
| Status | Recruiting |
| Started | September 15, 2026 |
| Main results expected | March 2027 |
| Study ends | March 2027 |
| Registry record updated | October 30, 2026 |
| Trial ID | NCT07788339 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 22–39 in the United States who were diagnosed with cancer between ages 15–39 and who regularly use social media.
✕Probably not a fit
Individuals who do not experience improvements in social connectedness or who do not engage with the online intervention content may see little to no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized trial will enroll up to 395 US-based young adults aged 22–39 who were diagnosed with cancer between ages 15–39. Participants undergo a 7-week protocol, with a 4-week intervention phase that uses a beta social media site called Invibe to present intervention or control content. After a baseline observation period, participants are randomized in week 3 to either the experimental or control arm and will have passive and forced exposure to posts within Invibe, followed by weekly surveys through week 7 to assess social and emotional well-being. The study aims to determine if the social connectedness intervention improves psychosocial outcomes compared with control.
Why it matters
Potential benefit: If successful, participants may experience improved social connection and emotional well-being during and after their cancer journey.
How similar studies have gone: Prior research in digital social interventions for cancer patients has shown mixed but growing evidence of psychosocial benefits in similar populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Are ages 22-39 * Received a cancer diagnosis between ages 15-39 * Use social media * Reside in the United States Exclusion Criteria: * Report high psychosocial health (≥4.5 mean of two mental health quality of life items) * Report being unable to take the study surveys because their schedule will not allow, they are not interested in taking the study surveys, or do not intend to complete the study surveys
Where it's running
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Allison Lazard, PhD — UNC Lineberger Comprehensive Cancer Center
- Study coordinator: Mirian Avendano-Galdamez, BA
- Email: Mirian_Avendano_Galdamez@med.unc.edu
- Phone: 984-974-0000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized navigation to support rural and Black women with endometrial cancer
This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.
-
One year vs two years of maintenance immunotherapy for endometrial cancer
This trial tests whether keeping pembrolizumab or dostarlimab for one year works as well as two years for people with advanced, recurrent, or metastatic endometrial cancer who completed initial chemo and anti-PD1 therapy.
-
NeoAdjuvant PD-1–Based Therapy in Resectable Advanced Melanoma (NASA)
In people with resectable stage IIIB–IV melanoma, this study tests whether two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab given before surgery can keep people alive at 2 years without needing additional adjuvant therapy.
-
Heart-friendly medicines to protect chest-area cancer patients from radiation damage
This Phase 2 trial tests whether taking atorvastatin and lisinopril can reduce heart damage in adults with chest-area cancers who receive radiation therapy.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC
In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.